Physician profile
Luke Stephan Erdoes
NPI 1558355511
$6,716.91
in general payments reported to CMS, 2019-2025
29 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $1,632 · 2021: $867 · 2022: $1,881 · 2023: $400 · 2024: $752 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $1,707.42 | 2021-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Cardiovascular Systems INC. | $1,087.71 | 2019-2020 | |
| Medtronic Vascular, INC. | $875.14 | 2019-2020 | |
| Medtronic, INC. | $759.05 | 2021-2024 | Endurant Iis |
| Philips North America LLC | $379.02 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $211.99 | 2020-2023 | Xarelto |
| W. L. Gore & Associates, INC. | $182.84 | 2019-2024 | Gore Excluder Thoracoabdominal Branch Endoprosthesis |
| Shockwave Medical, INC | $176.83 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $156.00 | 2023-2025 | Lifevest |
| Bolton Medical INC | $126.97 | 2019-2023 | Treo Abdominal Stent-Graft System |
| Abbott Laboratories | $117.18 | 2024 | Esprit |
| Daiichi Sankyo INC. | $111.10 | 2021-2023 | Injectafer |
| Pfizer INC. | $106.45 | 2019-2023 | |
| Edwards Lifesciences Corporation | $102.22 | 2019 | |
| Boston Scientific Corporation | $102.03 | 2019-2024 | Eluvia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lemaitre Vascular, INC. | $101.01 | 2019-2025 | Tyke, Patch, Pledget and Intracardiac, Xenosure Biologic Patch |
| Surmodics, INC. | $85.32 | 2023 | Sublime Radial Access Guide Sheath, Sublime Radial Access 018 Rx Pta Dilatation Catheter, Sublime 014 Rx Pta Balloon Dilatation Catheter |
| Novartis Pharmaceuticals Corporation | $59.43 | 2021-2024 | |
| Tactile Systems Technology INC | $52.83 | 2019-2022 | |
| Elutia, INC. | $46.14 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $27.86 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $26.71 | 2021-2022 | |
| Amgen INC. | $24.94 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.79 | 2021 | |
| Reflow Medical INC | $17.73 | 2024 | |
| Novo Nordisk INC | $14.88 | 2024 | Wegovy |
| Merck Sharp & Dohme LLC | $14.51 | 2021 | |
| Getinge USA Sales, LLC | $14.46 | 2021 | |
| Astellas Pharma US INC | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Erdoes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.